Literature DB >> 17964220

Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy.

A Gardulf1, M Borte, H D Ochs, U Nicolay.   

Abstract

The aims of the present study were to evaluate the health-related quality of life (HRQL) and treatment satisfaction (TS) of adults and children with primary antibody deficiencies (PAD) before and after the introduction of subcutaneous immunoglobulin G (SCIG) self-infusions at home and to identify prognostic factors (demographic/social, medical, patient/parent reported) for HRQL. 85 adults and 21 parents of children with PAD answered the SF-36 (adults), CHQ-PF50 (parents), and the LQI (adults and parents) at baseline and following 10 months of weekly self-administered SCIG infusions at home. The SCIG home therapy was associated with significant improvements in HRQL and TS, particularly in patients who had previously received IVIG therapy in hospital settings. Background factors that were found to be associated with HRQL changes in adults were age, serum IgG levels at month 10, concomitant joint/muscle/skeletal disorders, clinical study location and smoking status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964220     DOI: 10.1016/j.clim.2007.06.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  27 in total

1.  Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.

Authors:  Michael Borte; Isabella Quinti; Annarosa Soresina; Eduardo Fernández-Cruz; Bruce Ritchie; Dirk S Schmidt; Christine McCusker
Journal:  J Clin Immunol       Date:  2011-09-20       Impact factor: 8.317

2.  Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

Authors:  Nicolò Compagno; Francesco Cinetto; Gianpietro Semenzato; Carlo Agostini
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

3.  Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL.

Authors:  G H Jörgensen; A Gardulf; M I Sigurdsson; S Arnlaugsson; L Hammarström; B R Ludviksson
Journal:  Qual Life Res       Date:  2014-03       Impact factor: 4.147

4.  Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

Authors:  H B Niebur; C M Duff; G F Shear; D Nguyen; T K Alberdi; M J Dorsey; J W Sleasman
Journal:  Clin Exp Immunol       Date:  2015-07-07       Impact factor: 4.330

Review 5.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

6.  Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.

Authors:  M Borte; E Bernatowska; H D Ochs; C M Roifman
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

Review 7.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Authors:  S Jolles; J S Orange; A Gardulf; M R Stein; R Shapiro; M Borte; M Berger
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

8.  Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.

Authors:  R Gustafson; A Gardulf; S Hansen; H Leibl; W Engl; M Lindén; A Müller; L Hammarström
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

9.  Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.

Authors:  Suzanne Skoda-Smith; Troy R Torgerson; Hans D Ochs
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

Review 10.  Common variable immunodeficiency: etiological and treatment issues.

Authors:  Sean Deane; Carlo Selmi; Stanley M Naguwa; Suzanne S Teuber; M Eric Gershwin
Journal:  Int Arch Allergy Immunol       Date:  2009-07-01       Impact factor: 2.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.